Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s share price shot up 11.1% during trading on Thursday. The stock traded as high as C$0.20 and last traded at C$0.20. Approximately 296,140 shares changed hands during trading, an increase of 241% from the average daily volume of 86,934 shares. The stock had previously closed at C$0.18.
Medicenna Therapeutics Stock Performance
The firm has a 50 day moving average price of C$0.40 and a 200 day moving average price of C$0.51. The stock has a market cap of C$16.15 million, a PE ratio of -0.80 and a beta of 2.49. The company has a quick ratio of 4.65, a current ratio of 0.69 and a debt-to-equity ratio of -4.08.
Medicenna Therapeutics (TSE:MDNA – Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported C($0.04) earnings per share for the quarter. Medicenna Therapeutics had a negative return on equity of 861.02% and a negative net margin of 533,640.00%. As a group, research analysts forecast that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.
See Also
- Five stocks we like better than Medicenna Therapeutics
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
